ABSTRACT Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective treatment for patients with high-risk hematologic malignancies. Over the last decade, gut microbiota composition during allo-HCT has been associated with patients' outcomes. Treatment-related…
On May 13, 2026, the U.S. Food and Drug Administration (FDA) approved an all-oral regimen of decitabine–cedazuridine (DEC-C; ASTX727) plus venetoclax for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy…
Key Points For patients with AML treated with LIT, ELN 2024 and Beat AML 2024 best identify a favorable group. Allogeneic stem cell transplant improves survival, but patients classified as adverse risk by any system still have poor outcomes. Abstract Real-world validation of the…
In this issue of Blood, Muffly et al1 demonstrate in a phase 1 trial the feasibility and safety of CD117-targeted, precision preconditioning for allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) and myelodysplastic neoplasia (MDS). Almost 70…
Dr. Reshma Ramlal is a hematologist-oncologist at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. She specializes in bone marrow transplantation and cellular immunotherapy, with a clinical and research focus on allogeneic transplantation for myeloid malignancies, including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. She is particularly recognized for advancing safe and effective transplantation in the elderly population, offering individualized treatment plans that emphasize both survival and quality of life. In her clinical
